Canine Atopic Dermatitis Market to Cross US$ 431.0 Mn by 2035 as Pet Dermatology Advances Gain Traction | Latest Report by Transparency Market Research, Inc.
05. März 2025 07:30 ET
|
Transparency Market Research
Wilmington, Delaware, Transparency Market Research Inc. –, March 05, 2025 (GLOBE NEWSWIRE) -- The Canine Atopic Dermatitis Market (Marché de la dermatite atopique canine) is expected to expand...
Janus Kinase (JAK) Inhibitor Pipeline Market Insights Report 2025: Comprehensive Review of 50+ Companies and Respective 55+ Drugs
04. März 2025 10:27 ET
|
Research and Markets
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.The "Janus Kinase (JAK)...
Atopic Dermatitis Drugs Market Trends Analysis Report 2025-2030: Atopic Dermatitis Treatment Surges with 9.02% CAGR, Pushing Worldwide Market Near USD 30 Billion
21. Januar 2025 08:00 ET
|
Research and Markets
Dublin, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Route Of Administration, By Distribution Channel, By Region,...
Janus Kinase (JAK) Inhibitor Therapeutic Report 2024: Strategic Evaluation of Over 50 Companies and 55+ Pipeline Drugs
15. August 2024 11:04 ET
|
Research and Markets
Dublin, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The latest insights into the...
U.S. Inflammatory Bowel Disease Treatment Market Trends Analysis Report 2024-2030 Featuring Biogen, Novartis, Eli Lilly & Co, UCB, Celltrion, Merck & Co, and Johnson & Johnson
25. Juni 2024 10:57 ET
|
Research and Markets
Dublin, June 25, 2024 (GLOBE NEWSWIRE) -- The "U.S. Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report by Type, Drug Class, Route Of Administration, Distribution...
JAK Inhibitor Market to Register Immense Growth by 2034, Predicts DelveInsight | Key Companies - Eli Lilly and Company, Incyte Corporation, Dompé Farmaceutici S.p.A, Sanofi, Celgene, AstraZeneca, Karyopharm Therapeutics
15. Mai 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 15, 2024 (GLOBE NEWSWIRE) -- JAK Inhibitor Market to Register Immense Growth by 2034, Predicts DelveInsight | Key Companies - Eli Lilly and Company, Incyte Corporation, Dompé...
Janus Kinase (JAK) Inhibitor Market Forecast 2024-2034: Analyzes Trends Likely to Shape Future Opportunities
14. März 2024 04:30 ET
|
Research and Markets
Dublin, March 14, 2024 (GLOBE NEWSWIRE) -- The "Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ...
Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market
23. Februar 2024 13:50 ET
|
Spherix Global Insights
EXTON, PA, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Amidst the array of advanced treatment avenues available for rheumatoid arthritis (RA), ranging from legacy TNF inhibitors and their newer biosimilar...
When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…
30. November 2023 10:59 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 30, 2023 (GLOBE NEWSWIRE) -- With the Ulcerative Colitis (UC) market set to heat up in the coming months, the JAK class seems poised to become a dominant treatment,...
XELJANZ for Ulcerative Colitis (UC) Pipeline Report 2023: Drug Market Insights and Forecasts, 2019-2032 - Focus on 7 Major Markets
23. November 2023 11:23 ET
|
Research and Markets
Dublin, Nov. 23, 2023 (GLOBE NEWSWIRE) -- The "XELJANZ Market Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. "XELJANZ Market Drug...